Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxcel Therapeutics ( (BTAI) ) just unveiled an announcement.
On April 1, 2026, BioXcel Therapeutics, Inc. reported that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for IGALMI, targeting the acute treatment of agitation linked to bipolar disorders or schizophrenia in at-home, outpatient use. The agency set a Prescription Drug User Fee Act target action date of November 14, 2026, marking a key regulatory milestone that could expand IGALMI’s use beyond clinical settings and potentially broaden the company’s reach in psychiatric care.
The most recent analyst rating on (BTAI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Neutral.
The score is held down primarily by very weak financial performance (ongoing losses, cash burn, negative equity and elevated debt) and a bearish technical backdrop (below key moving averages with negative MACD). Positive IGALMI at-home regulatory/commercial events provide some offset, but valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing neuroscience treatments, including IGALMI, for psychiatric conditions such as bipolar disorders and schizophrenia in both clinical and potential at-home settings.
Average Trading Volume: 1,385,354
Technical Sentiment Signal: Sell
Current Market Cap: $36.28M
Learn more about BTAI stock on TipRanks’ Stock Analysis page.